Prestige Consumer Healthcare Inc. $PBH Stock Position Decreased by Bessemer Group Inc.

Bessemer Group Inc. reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 26.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 277,600 shares of the company’s stock after selling 100,620 shares during the period. Bessemer Group Inc. owned 0.56% of Prestige Consumer Healthcare worth $17,323,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after purchasing an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after buying an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares in the last quarter. Jane Street Group LLC increased its position in Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after acquiring an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. increased its position in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the period. 99.95% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.40% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $66.48 on Friday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $90.04. The firm’s 50 day simple moving average is $63.19 and its 200-day simple moving average is $64.06. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 2.51. The company has a market cap of $3.20 billion, a P/E ratio of 17.59, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm’s quarterly revenue was down 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

More Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Management highlighted progress restoring Clear Eyes supply and said availability is improving, which supports a rebound in that brand’s sales going forward. Prestige Consumer Healthcare narrows fiscal 2026 revenue outlook to $1.1B while advancing Clear Eyes supply recovery
• Positive Sentiment: The company narrowed and finalized its fiscal‑2026 revenue outlook to about $1.1 billion, which reduces uncertainty around full‑year expectations and may reassure investors. Prestige Consumer Healthcare Q3 revenue tops estimates, narrows guidance
• Neutral Sentiment: Management posted the full slide deck and call transcript; these provide detail on segment trends, margins and working‑capital dynamics for investors doing deeper diligence. Q3 2026 Earnings Call Transcript
• Negative Sentiment: Q3 results showed a small EPS miss: $1.14 reported vs. ~$1.16 consensus, and revenue of ~$283.4M was down roughly 2.4% year‑over‑year—factors that are short‑term headwinds for the stock. Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
• Negative Sentiment: Fiscal‑2026 EPS guidance was set at 4.54 (company’s figure), essentially flat-to-slightly below some sell‑side consensus (~4.55), leaving limited upside in near‑term estimates. Press release: Third Quarter and Year-to-Date Fiscal 2026 Results

Analyst Ratings Changes

PBH has been the subject of several research analyst reports. Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Oppenheimer dropped their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus price target of $80.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).